-
公开(公告)号:JP2010209123A
公开(公告)日:2010-09-24
申请号:JP2010152053
申请日:2010-07-02
申请人: Novartis Ag , ノバルティス アーゲー
IPC分类号: A61K45/00 , C07D285/28 , A61K31/19 , A61K31/196 , A61K31/41 , A61K31/4184 , A61K31/44 , A61K31/4422 , A61K31/455 , A61K31/549 , A61K45/06 , A61P3/10 , A61P5/00 , A61P5/42 , A61P7/10 , A61P9/00 , A61P9/04 , A61P9/06 , A61P9/10 , A61P9/12 , A61P9/14 , A61P13/02 , A61P13/12 , A61P17/00 , A61P25/06 , A61P25/28 , A61P27/02 , A61P27/06 , A61P43/00 , C07D211/90 , C07D257/04 , C07D401/12
CPC分类号: A61K31/196 , A61K31/19 , A61K31/4184 , A61K31/44 , A61K2300/00
摘要: PROBLEM TO BE SOLVED: To provide an antihypertensive drug which leads a decrease in blood pressure, and has an auxiliary form of action that alleviates hypertensive various morbid sequela and some other cardiovascular diseases.
SOLUTION: An antihypertensive drug is found which leads a decrease in blood pressure, and has an auxiliary form of action that alleviates hypertensive various morbid secondary diseases and some other cardiovascular diseases.
COPYRIGHT: (C)2010,JPO&INPIT摘要翻译: 要解决的问题:提供导致血压降低的抗高血压药物,并且具有减轻高血压各种病态后遗症和一些其它心血管疾病的辅助作用形式。 解决方案:发现导致血压降低的抗高血压药物,具有减轻高血压各种病态继发性疾病和一些其他心血管疾病的辅助作用形式。 版权所有(C)2010,JPO&INPIT
-
公开(公告)号:JP2010090173A
公开(公告)日:2010-04-22
申请号:JP2010010967
申请日:2010-01-21
申请人: Novartis Ag , ノバルティス アーゲー
IPC分类号: A61K45/06 , A61K31/16 , A61K31/40 , A61K31/401 , A61K31/41 , A61K31/4439 , A61K31/454 , A61P3/04 , A61P3/06 , A61P3/10 , A61P5/14 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/10 , A61P9/12 , A61P13/12 , A61P15/10 , A61P17/00 , A61P19/04 , A61P27/02 , A61P27/06 , A61P27/12 , A61P43/00
CPC分类号: A61K31/454 , A61K31/16 , A61K31/40 , A61K31/41
摘要: PROBLEM TO BE SOLVED: To provide a combined medicine which is effective for the prevention, delay of progress or treatment of malady and disease.
SOLUTION: A combination contains a DPP IV inhibitor and a cardiovascular compound effective for the prevention, delay of progress or treatment of malady and disease selected from the group consisting of hyperpiesia, congested heart failure, left ventricular hypertrophy, peripheral arterial disease, diabetes, especially type 2 diabetes, diabetic retinopathy, macular degeneration, cataract, diabetic nephropathy, glomerulosclerosis, chronic kidney failure, diabetic neuropathy, syndrome X, premenstrual syndrome, coronary heart disease, angina cordis, thrombosis, arterial sclerosis, myocardial infarction, transient ischemic attack, apoplexy, vascular restenosis, hyperglycaemia, hyperinsulinemia, hyperlipidemia, hypertriglyceridemia, insulin resistance, impaired glucose metabolism, conditions of impaired glucose tolerance, conditions of impaired fasting plasma glucose, obesity, erectile dysfunction, disease of skin and connective tissue, podalic tumor formation and chronic ulcerative colitis, endothelium dysfunction and impaired vascular compliance.
COPYRIGHT: (C)2010,JPO&INPIT摘要翻译: 要解决的问题:提供一种有效预防,延缓进展或治疗疾病和疾病的联合药物。 解决方案:组合包含DPP IV抑制剂和心血管化合物,其有效预防,延迟进展或治疗疾病和疾病,其选自高血压,充血性心力衰竭,左心室肥大,外周动脉疾病, 糖尿病,特别是2型糖尿病,糖尿病性视网膜病变,黄斑变性,白内障,糖尿病性肾病,肾小球硬化,慢性肾功能衰竭,糖尿病性神经病变,X综合征,经前综合征,冠心病,心绞痛,血栓形成,动脉硬化,心肌梗死, 攻击,中风,血管再狭窄,高血糖症,高胰岛素血症,高脂血症,高甘油三酯血症,胰岛素抵抗,葡萄糖代谢受损,葡萄糖耐量降低的病症,空腹血糖异常,肥胖症,勃起功能障碍,皮肤病和结缔组织疾病,扁桃体肿瘤形成 和慢性溃疡性大肠杆菌 Tis,内皮功能障碍和血管依从性受损。 版权所有(C)2010,JPO&INPIT
-